HSPB8 and plasma cell myeloma: Some studies demonstrated that HSPB8 is highly expressed in breast cancers [46, 47, 50–55], myeloma [56], ovarian cancer [57], gastric cancer [58], lung cancer [59], and cholangiocarcinoma [60] where it increases cell proliferation, migration and tumorigenic activity.